1,721,052 research outputs found
Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma
Full text linkPurpose: CD19 is a cell surface protein that is found on both healthy and malignant B cells. Accordingly, it has become an important target for novel treatments for non-Hodgkin lymphomas and B-cell leukaemia. Three anti-CD19 monoclonal antibodies with distinct mechanisms of action have been developed for the treatment of B-cell malignancies. Methods: We reviewed the preclinical and clinical data on the development of the newly approved anti-CD19 monoclonal antibodies blinatumomab, tafasitamab and loncastuximab tesirine, and consider their place in the treatment of relapsed or refractory B-cell malignancies. Results: Blinatumomab is a bispecific T-cell engager that binds to both CD19 on B cells and CD3 on T cells, facilitating antibody-dependent cytotoxicity. Blinatumomab significantly prolongs overall survival in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia, although cytokine release syndrome and severe neurotoxicity may necessitate discontinuation. Tafasitamab, which has modified anti-CD19 Fab and Fc regions, has significantly enhanced affinity for both CD19 and effector cell receptors compared with unmodified anti-CD19. In L-MIND, tafasitamab plus lenalidomide provided an overall response rate (ORR) of 57.5% in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in patients non-transplant eligible. Loncastuximab tesirine is an antibody–drug conjugate that has been studied as monotherapy and in combination with ibrutinib in 3L + relapsed or refractory DLBCL. The ORR was 48.3% in a phase II trial of loncastuximab tesirine. The optimal place of anti-CD19 monoclonal antibodies in therapy has yet to be determined, but the prospect of improved outcomes for at least some patients with treatment-resistant B-cell malignancies appears likely, particularly in those with limited therapeutic options and poor prognosis
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Valutazione della topografia superficiale di impianti macchinati ed impianti sabbiati e mordenzati.
No full textValutazione della topografia superficiale di impianti macchinati e sabbiati e mordenzati / Atomic force microscope for implant surface study
No full textScopo del lavoro Il presente studio analizza mediante l’uso di un microscopio a forza atomica (AFM) la ruvidità di superficie di impianti macchinati messi a confronto con impianti sabbiati e mordenzati per meglio comprendere le reali condizioni fisiche osservabili sulla superficie e che influenzano l’osteointegrazione. Materiali e metodi L’AFM ricostruisce l’immagine della superficie di un campione attraverso una scansione per punti di un raggi laser consentendo di ottenere una immagine tridimensionale della superficie analizzata. Sono state realizzate scansioni a 3, 30 e 60 mm; il tipo di matrice utilizzata è stato di 256x256 per un totale di 65.536 scansioni. Risultati e conclusioni La ruvidità media di superficie risulta apprezzabilmente differente tra le due superfici implantari analizzate a netto vantaggio degli impianti sabbiati e mordenzati, ma sono necessari ulteriori studi per definire le proprietà biologiche e biomeccaniche ideali.Aim In this study surface roughness of machined implants is compared to sandblasted-acid etched implants by atomic force microscope analysis in order to understand the real physical conditions that is possible to observe on surface and that influence osseointegration. AFM reconstructs the surface image of a sample by scanning per point through laser beam and achieving a three-dimensional image. A total of 3, 30 and 60 mm scans were made and a 256x256 matrix was used for a totals of 65536 scans. Results and conclusions Mean surface roughness is different between the two analyzed surfaces is in favour of sandblasted-acid etched implants. However further studies are needed to define ideal biological and biomechanical properties
- …
